Enhancement of de novo NAD+ Biosynthesis by Novel ACMSD Inhibitors Improves Mitochondrial Function in iPSC-Derived Human Liver Organoid Models of Steatohepatitis (AASLD 2022, Poster #2441)
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
